North Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, as well as the Technical University Dortmund in an AI network for cancer medicine.
Novartis’ $12B Avidity bet suffers Phase 3 blow
Latest NewsNovartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity Biosciences, failed to significantly improve hand function over placebo in the Phase 3 HARBOR study in myotonic dystrophy type 1.
Germany’s NRW state bets €200M on AI-powered cancer research
Latest NewsNorth Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, as well as the Technical University Dortmund in an AI network for cancer medicine.
Vaxdyn raises €11M Series A to test AMR vaccine
Latest NewsSpanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor Biovance Capital led the round with a €4 million investment, joined by the European Innovation Council (EIC) Fund and the Impacto Andalusia fund managed by Arcano Partners.
BioInnovation Institute backs six startups with €8M
Latest NewsCopenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million.
New CEO took over the reins
AppointmentsAt the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer for nearly seven years.
Novartis’ Lp(a) drug misses Phase 3 endpoint
Latest NewsNovartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk factor.
Remote Bioprocess Monitoring with BioNsight® cloud: Every run in one view, from 100 mL development to production
ProductsNovartis commits $3.2B to subcutaneous delivery
Latest NewsNovartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen’s technology for turning intravenous biologics into subcutaneous drugs. Behind the eye-catching figure is more than patient convenience: Drug delivery is becoming an increasingly important tool for lifecycle management and emerging drug classes.
Menarini pays up to €726M for Chinese obesity drug
Latest NewsItalian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every two weeks, for €62 million upfront, up to €664 million in milestones, and “double-digit” royalties. Menarini will handle regulatory submissions and commercialization across 39 European markets.
Transgene cancer vaccine keeps patients relapse-free for three years
Latest NewsFrench biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three of 16 patients in the control arm relapsed.